Clinical Trials Logo

Chondrosarcoma clinical trials

View clinical trials related to Chondrosarcoma.

Filter by:

NCT ID: NCT01336803 Completed - Osteosarcoma Clinical Trials

Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI

Osteosarcoma
Start date: August 2011
Phase: Phase 2
Study type: Interventional

This pilot trial studies the differentiation of bone sarcomas and osteomyelitis with ferumoxytol-enhanced magnetic resonance imaging (MRI). Imaging procedures that allow doctors to more accurately differentiate between malignant bone sarcomas and osteomyelitis may help in diagnosing patients correctly and may result in more timely treatment.

NCT ID: NCT01330966 Completed - Chondrosarcoma Clinical Trials

Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma

Start date: April 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the effectiveness and safety of single agent pazopanib in subjects with chondrosarcoma.

NCT ID: NCT01310816 Completed - Clinical trials for Conventional Chondrosarcoma

A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma

Start date: February 2011
Phase: Phase 2
Study type: Interventional

IPI-926 is an inhibitor of the hedgehog pathway. IPI-926 may improve therapeutic outcomes in patients with Chondrosarcoma.

NCT ID: NCT01267955 Active, not recruiting - Clinical trials for Mesenchymal Chondrosarcoma

Vismodegib in Treating Patients With Advanced Chondrosarcomas

Start date: December 21, 2010
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well vismodegib works in treating patients with chondrosarcomas that have spread to other places in the body and usually cannot be cured or controlled with treatment. Drugs used in chemotherapy, such as vismodegib, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

NCT ID: NCT01182753 Recruiting - Chondrosarcoma Clinical Trials

Trial of Proton Versus Carbon Ion Radiation Therapy in Patients With Low and Inter-mediate Grade Chondrosarcoma of the Skull Base

CSP12C
Start date: August 2010
Phase: Phase 3
Study type: Interventional

The study is a prospective randomised clinical phase III trial. Proton therapy is the gold standard in the treatment of low and intermediate grad chondrosarcomas of the skull base. However, high-LET beams such as carbon ions theoretically offer biologic advantages by enhanced biologic effectiveness in slow-growing tumors. Up until now it was impossible to compare two different particle therapies, i.e. proton and carbon ion therapy directly with each other. The aim of this study is to find out, whether the biological advantages of carbon ion therapy mentioned above can also be clinically confirmed.

NCT ID: NCT01154452 Completed - Clinical trials for Gastrointestinal Stromal Tumor

Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma

Start date: June 2010
Phase: Phase 1/Phase 2
Study type: Interventional

This randomized phase I/II clinical trial is studying the side effects and best dose of gamma-secretase/notch signalling pathway inhibitor RO4929097 when given together with vismodegib and to see how well they work in treating patients with advanced or metastatic sarcoma. Vismodegib may slow the growth of tumor cells. Gamma-secretase/notch signalling pathway inhibitor RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving vismodegib together with gamma-secretase/notch signalling pathway inhibitor RO4929097 may be an effective treatment for sarcoma.

NCT ID: NCT00928525 Completed - Clinical trials for Advanced Desmoid Tumor

Imatinib in Patients With Desmoid Tumor and Chondrosarcoma

Basket 1
Start date: May 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether Imatinib Mesylate is active in diseases - such as Desmoid Tumor and Chondrosarcoma - expressing the receptor for the platelet-derived growth factor (PDGF) both in its isoform alpha and beta

NCT ID: NCT00797602 Completed - Chondrosarcomas Clinical Trials

Proton Therapy for Chordomas and/or Chondrosarcomas

CH01
Start date: January 2007
Phase: N/A
Study type: Observational

The purpose of this study is to collect information from medical records to see what effects proton beam radiation has on cancer and analyze possible side effects.

NCT ID: NCT00720174 Completed - Clinical trials for Recurrent Adult Soft Tissue Sarcoma

Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma

Start date: June 2008
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of cixutumumab given together with doxorubicin hydrochloride and to see how well they work in treating patients with unresectable, locally advanced, or metastatic soft tissue sarcoma. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving monoclonal antibody cixutumumab together with doxorubicin hydrochloride may kill more tumor cells.

NCT ID: NCT00592748 Completed - Chondrosarcoma Clinical Trials

Charged Particle RT for Chordomas and Chondrosarcomas of the Base of Skull or Cervical Spine

Start date: June 1999
Phase: Phase 1/Phase 2
Study type: Interventional

The primary purpose of this study is to determine if the administration of a higher dose would decrease the chance of tumor recurrence, compared to the risk of tumor recurrence with a lower dose. Most of the treatment will be given protons, but participants may receive a small portion of treatment with x-rays, because less radiation is given to the skin with x-rays. This study uses two slightly different doses of radiation It is not clear at this time which of the dose levels is better.